ArticleReproductive biology and endocrinology : RB&E2025
Re-biopsy and modified biopsy in mosaic human embryos with simple segmental chromosomal deletion.
Article in Reproductive biology and endocrinology : RB&E, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere is a considerable proportion of false positive results when the result of preimplantation genetic testing for aneuploidy is chromosomal mosaicism. The aim of this study was to assess the concordance among clinical trophectoderm biopsy, second trophectoderm biopsy, and inner cell mass biopsy in mosaic human embryos with segmental deletion and evaluate a modified biopsy protocol.
methodsThis retrospective study included 100 pretested blastocysts, which were classified as segmental deletion mosaics with one to two chromosomes were affected, donated by 84 couples in a single, high-volume fertility center in Beijing China. Re-biopsy was taken from the inner cell mass and two symmetrical trophectoderm sites near the inner cell mass in each embryo. Samples from the inner cell mass and one of the two trophectoderm were prepared for modified protocol, which isolated portions into single cells, the cells with normal morphology were collected and cell debris were removed. Re-biopsy samples were analyzed by next-generation sequencing. Main outcome measures were concordance between clinical biopsy and blastocyst, and segmental mosaicism in modified protocol.
resultsOnly six (6.5%) of 92 inner cell mass samples presented with concordant chromosomal aberrations, four (4.3%) presented with de novo segmental abnormalities, and 82 (89.1%) did not show any segmental abnormalities. For the trophectoderm samples, 62 (66.7%) of 93 s biopsies and 76 (80%) of 95 modified biopsies did not show any segmental deletion or duplication. The modified biopsy protocol was associated with fewer segmental abnormalities (20% versus 33.3%; odds ratio: 0.5, 95% confidence interval: 0.26 to 0.97) and fewer segmental deletion mosaics (10.5% versus 23.7%; odds ratio: 0.38, 95% confidence interval: 0.17 to 0.85) compared with the second biopsy.
conclusionsA clinical mosaic embryo with simple segmental deletion was extremely low predictive of the embryo. Removal of cell debris from biopsy samples may reduce the incidence of segmental deletion mosaics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.